Sutter Health Hospitals Deploy Wearable Ultrasound Tech to Personalize Fluid Management for Sepsis
Major California health system leads adoption of FloPatch, a device offering clinical teams real-time data to reduce the risk of giving too much or too little fluid
Article content
Article content
both of which can lead to serious complications
Article content
SACRAMENTO, Calif. & LOS ANGELES — Sutter Health, an integrated not-for-profit healthcare system based in Northern California, and Flosonics Medical today announced an expansion of the deployment of FloPatch, the first wireless wearable Doppler ultrasound device, across multiple hospital sites to support more precise and timely intravenous (IV) fluid management. This multisite deployment includes Sutter's Alta Bates Summit Medical Center, Summit Campus in Oakland and Sutter Santa Rosa Regional Hospital in Sonoma County. Implementations span the Emergency Department, Intensive Care Unit, Medical-Surgical Unit and Telemetry Unit. With these additions, six Sutter hospital campuses have now deployed FloPatch over the past year and include Sutter's Eden Medical Center in Castro Valley, Sutter's CPMC in San Francisco at CPMC Van Ness, Davies and Mission Bernal Campuses.
IV fluid overload is a common complication in emergency and intensive care settings, in part because predicting a patient's response to fluids is complex. Individual needs can vary widely and shift quickly during critical illness. In studies of patients with sepsis and septic shock – a life-threatening condition caused by the body's overwhelming response to infection – nearly one-third were found to be fluid unresponsive¹. Without early identification of fluid unresponsiveness, patients may receive excessive fluids, increasing their risk of serious complications such as pulmonary edema, where fluid accumulates in the lungs. By some estimates, fluid overload can extend the average hospital stay by three days and increase healthcare costs by more than $15,000 per patient².
Article content
FloPatch is an FDA-cleared, wearable device that provides clinicians with a fast and non-invasive way to perform hemodynamic assessments, measuring a patient's heart and blood flow response to IV fluids to help guide personalized fluid therapy. Clinical studies have shown that dynamic fluid assessments can reduce the need for mechanical ventilation and renal replacement therapy ³,⁴, decrease ICU length of stay⁴, and are associated with lower mortality⁵.
Article content
'Our previous method of assessing fluid responsiveness was cumbersome and time-consuming. We often had to pull ICU nurses to perform evaluations in other units, which was disruptive and inefficient,' said Dr. Nader Emami, ICU medical director at Sutter Santa Rosa Regional Hospital. 'FloPatch streamlines the process with a simple, wearable device that empowers any member of the care team to perform this essential assessment faster and easier.'
Article content
'In emergency care, we often treat patients with complex needs, including people with sepsis,' said Dr. John Skovran, Emergency Department medical director at Sutter's Alta Bates Summit Medical Center, Summit Campus. 'We need a fast, reliable way to determine whether they'll benefit from fluids or be harmed by them. FloPatch gives us that clarity at the bedside in minutes, helping us make confident, timely decisions.'
Article content
Joe Eibl, chief executive officer and co-founder of Flosonics Medical, noted: 'Sutter Health's multisite adoption of FloPatch reflects a growing recognition that wearable, real-time technologies play a transformative role in patient care. It's a great example of how forward-thinking health systems are meeting critical challenges with innovation.'
Article content
Sutter Health prioritized staff training and thoughtfully integrated FloPatch into clinical workflows to make it a seamless part of care in intensive care and emergency medicine departments.
Article content
About Sutter Health:
Article content
Sutter Health is a not-for-profit healthcare system dedicated to providing comprehensive care throughout California. Committed to health equity, community partnerships, and innovative, high-quality patient care, Sutter Health is pursuing a bold new plan to reach more people and make excellent healthcare more connected and accessible. Currently serving more than 3.5 million patients, thanks to our dedicated team of more than 60,500 employees and clinicians, and 14,000+ physicians and advanced practice clinicians, with a unified focus on expanding care to serve more patients.
Article content
Sutter delivers exceptional and affordable care through its hospitals, medical groups, ambulatory surgery centers, urgent care clinics, telehealth, home health, and hospice services. Dedicated to transforming healthcare, at Sutter Health, getting better never stops.
Article content
Learn more about how Sutter Health is transforming healthcare at sutterhealth.org and vitals.sutterhealth.org.
Article content
About Flosonics Medical:
Article content
Flosonics Medical is a medical device company engaged in the research and development of innovative ultrasound technology. Founded in 2015, the company's mission is to improve patient care and the practice of medicine through technology-enabled solutions and groundbreaking clinical research. For more information, please visit
Article content
.
Article content
¹ Hernández G, Ospina‑Tascón GA, Damiani LP, et al; ANDROMEDA‑SHOCK Investigators. Effect of a resuscitation strategy targeting peripheral perfusion status vs serum lactate levels on 28‑day mortality among patients with septic shock: the ANDROMEDA‑SHOCK randomized clinical trial. JAMA. 2019 Feb 19;321(7):654–664. doi:10.1001/jama.2019.0071
Article content
Article content
³ Douglas IS, Alapat PM, Corl KA, Exline MC, Forni LG, Holder AL, et al. Fluid Response Evaluation in Sepsis Hypotension and Shock: A Randomized Clinical Trial. Chest. 2020 Oct;158(4):1431–1445. doi:10.1016/j.chest.2020.04.025
Article content
Article content
⁴ Latham HE, Bengtson CD, Satterwhite L, et al. Stroke volume–guided resuscitation in severe sepsis and septic shock improves outcomes. J Crit Care. 2017 Dec;42:42–46. doi:10.1016/j.jcrc.2017.06.028
Article content
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Media Contacts:
Article content
Jamie Gray, Flosonics Medical,
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
3 hours ago
- Globe and Mail
Boster Bio Revolutionizes IHC Services With Free Antibody Validation, Setting Industry Standards
Boster Bio pioneers free antibody validation, revolutionizing IHC services with guaranteed reagent reliability, setting new standards for reproducible research in biotech and pharmaceutical development. Boster Biological Technology (Boster Bio) is transforming the antibody industry with its reliable free antibody validation, providing precise staining and detection solutions for tissue samples. A leading provider of immunohistochemistry services (IHC services), the company has emerged as a game-changer for researchers demanding accuracy and transparency. With its commitment to antibody validation services that ensure reproducible results, Boster Bio addresses a critical pain point in biomedical research. Researchers no longer need to risk failed experiments due to untested reagents, as the company's approach ensures that every antibody meets high specificity and sensitivity standards before reaching the lab. Unlike competitors, Boster Bio provides detailed validation data upfront, allowing researchers to make informed decisions. The antibody validation process employs stringent testing, including Western blot, ELISA, and IHC cross-verification. Each antibody undergoes performance checks with openly accessible validation data, representing a notable milestone in the industry. Additionally, Boster Bio's responsive technical support team assists researchers in optimizing experiments, while flexible bulk and custom service options cater to diverse project needs. Fast shipping, a satisfaction guarantee, and openly shared validation protocols reinforce its commitment to scientific integrity. Combining cutting-edge technology with customer-centric policies, Boster Bio puts researchers first, setting a new standard for trust and efficiency in immunohistochemistry services and antibody supply. What sets it apart is its dedication to free antibody validation, a service typically offered by competitors for a fee. For more information, visit "Antibody reproducibility is a major challenge in life sciences. By offering free antibody validation, we eliminate guesswork and empower scientists with data-backed confidence in their reagents. This isn't just a service, it's our commitment to accelerating credible research," said CJ Xia, Founder of Boster Bio. With over 30 years of experience in antibody and immunoassay development, Boster Bio has established itself as a trusted leader in life science research. Serving researchers globally, the company has developed more than 20,000 high-quality antibodies and 2,000 ELISA kits. Backed by numerous peer-reviewed publications and citations in prestigious journals, Boster Bio has set industry benchmarks, earning recognition from academic and pharmaceutical institutions worldwide for its innovations in immunohistochemistry services and antibody validation. Boster Bio offers researchers advanced IHC protocols, offering both single and multiplex IHC/immunofluorescence panels tailored to research needs. Utilizing fully automated Leica Bond systems, the company ensures precision and reproducibility in staining while delivering fast turnaround times, typically just one to two weeks after sample receipt. With extensive experience supporting IHC for IND studies and regulatory submissions, Boster Bio is committed to helping researchers meet stringent compliance requirements. Additionally, the team specializes in developing custom IHC protocols optimized for specific targets and tissue types, enhancing detection sensitivity and accuracy. These capabilities make Boster Bio a trusted partner for high-quality, efficient, and regulatory-ready IHC solutions. Boster Bio excels in providing comprehensive IHC services and caters to the academic, pharmaceutical, and biotech sectors worldwide. Covering a wide range of applications, including cancer research, neuroscience, and immunology, the company offers access to over 3,000 pre-validated antibodies, ELISA kits, protein assays, and custom antibody development. By consistently delivering rigorously tested reagents with comprehensive validation data, Boster Bio continues to accelerate scientific discovery while maintaining exceptional standards of quality and reproducibility. For scientists prioritizing accuracy, Boster Bio's free antibody validation and comprehensive immunohistochemistry services offer an unmatched advantage, eliminating costly guesswork and ensuring reproducible results. About the Company: Boster Biological Technology (Boster Bio), based in Pleasanton, CA, is a leading provider of high-quality immunohistochemistry services and antibody validation solutions. Known for its free antibody validation, the company ensures researchers receive rigorously tested, reproducible antibodies, addressing a critical need in biomedical science. Offering ELISA kits, protein assays, and custom antibody development, Boster Bio serves academic, pharmaceutical, and biotech sectors worldwide. Media Contact Company Name: Boster Biological Technology Contact Person: CJ Xia Email: Send Email Phone: (888) 466-3604 Address: 3942 Valley Ave City: Pleasanton State: CA 94566 Country: United States Website:
National Post
5 hours ago
- National Post
Gate Bioscience Enters into a Collaboration and License Agreement with Lilly to Discover and Develop Molecular Gate Medicines
Article content BRISBANE, Calif. — Gate Bioscience, a biotechnology company developing molecular gates, a new class of small molecule drugs to eliminate disease-causing proteins at their source, today announced a collaboration and license agreement with Eli Lilly and Company ('Lilly') to discover, develop, and commercialize molecular gate therapeutics. The collaboration will leverage Gate's molecular gate drug discovery engine to identify molecular gates capable of eliminating specific difficult-to-drug proteins, bringing forth medicines with a new mechanism of action for diseases of high unmet medical need. Article content 'This collaboration fuels our vision to make molecular gates into medicines,' said Jordi Mata-Fink, Ph.D., co-founder and CEO of Gate. 'Our drugs eliminate disease-causing proteins at their source with a convenient pill. Lilly's expertise in developing innovative therapeutics to address unmet medical needs for the benefit of patients stands apart. Lilly is an ideal partner for Gate as we develop the first wave of molecular gate drugs.' Article content Under the terms of the agreement, Gate will receive an upfront payment and equity investment, will be eligible to receive milestone payments upon achievement of certain development, regulatory, and commercial milestones, as well as tiered royalties on global net sales. Gate can also receive certain preclinical R&D support from Lilly ExploR&D, a pillar of Lilly Catalyze360, for their internal programs. Article content 'Lilly has shown its commitment to building the biotech ecosystem through win-win partnerships with innovative start-up companies,' said Vineeta Agarwala, M.D., Ph.D., board member at Gate and general partner at a16z Bio + Health. 'With this collaboration, Lilly gains access to a transformative new drug modality and Gate taps into Lilly's deep expertise in delivering meaningful therapeutics. Ultimately, patients will be the big winners.' Article content About Gate Bioscience Article content Gate Bioscience is creating a new class of medicines called molecular gates, small molecules that eliminate a disease-causing secreted or membrane protein at its source. Secreted and membrane proteins pass through a common channel in the cell before they are secreted into the body. Molecular Gates recognize and block a specific protein from crossing the channel, causing it to be degraded by the cell instead of being secreted. By eliminating the harmful protein at its source, Gate aims to eliminate the disease for patients. Founded in 2021, Gate is backed by Versant Ventures, a16z Bio + Health, ARCH Venture Partners, and GV. Learn more at Article content Article content Article content Article content
National Post
a day ago
- National Post
Why biohacker Bryan Johnson wants to sell his anti-aging business to build a new religion
Tech entrepreneur and longevity crusader is thinking of ditching his 'pain-in-the-ass' anti-aging nutrition and supplements company to focus on his 'Don't Die' movement, a community of likeminded biohackers 'united in defeating all causes of human and planetary death.' Article content In a lengthy interview with Wired, the 47-year-old California multimillionaire said he is 'so close' to shutting down or selling Blueprint, a wellness company devoted to 'maximally slowing' aging and reversing aging that's already occurred. Article content Article content 'I've been talking to people about this. I don't need the money, and it's a pain-in-the-ass company,' Johnson told Wired's Katie Drummond. Article content Article content Johnson said Blueprint evolved from his own personal search for a clean, low-in-heavy-metals protein powder into a business venture that was just 'trying to do people a solid. The problem is now people see the business and give me less credibility on the philosophy side. I will not make that trade off … So yeah, I don't want it.' Article content The self-described most measured human on the planet, Johnson takes 40 odd vitamins and supplements daily as well as hundreds of daily measurements of his heart, liver, lungs, kidneys and other body organs so that they may 'speak for themselves what they need to be in their ideal state.' Article content In 2023, Johnson, his then 17-year-old son and Johnson's father participated in a multi-generational plasma exchange. Johnson received plasma from a litre of blood siphoned from his son at a Texas spa in the hope his son's blood would make him younger. Article content The plasma swap apparently had a null effect: In January, Johnson posted on X that he was no longer injecting his son's blood and had 'upgraded' to another controversial plasma protocol. Article content I am no longer injecting my son's blood. I've upgraded to something else: total plasma exchange. Steps: 1. Take out all blood from body 2. Separate plasma from blood 3. Replace plasma with 5% albumin & IVIG Here's my bag of plasma. Who wants it? 🧵 — Bryan Johnson (@bryan_johnson) January 28, 2025 Article content Johnson eats all the day's food before noon and sticks to a strict high-fibre, 'veggies and legumes,' no alcohol, no sugar diet that makes him feel sharper while avoiding 'post meal dead zones,' he's shared on X. Article content Last year, in a therapy dubbed 'Project Baby Face,' Johnson attempted to restore volume he's lost on his face from a calorie-reduced diet with fat injections in his temple, cheeks and chin. He didn't have enough of is own body fat so he used donor fat. It didn't go well: 'Immediately following the injections, my face began to blow up,' Johnson posted on Instagram. 'And then it got worse, and worse, and worse until I couldn't even see,' a severe allergic reaction. Article content What is Project Blueprint? Article content Johnson has explained how, In 2021, 'I endeavoured to figure out proximity to longevity escape velocity. How far away are we from one year of chronological time passing and one staying the same age biologically? I called this Project Blueprint.'
